Sitemap

Vol.9 - No.3 (July 2018)

REVIEW ARTICLES

IAPP/amylin and β-cell failure: implication of the risk factors of type 2 diabetes

A. Kanatsuka, S. Kou, H. Makino 143

ORIGINAL ARTICLES

Factors involved in decreasing the therapeutic effect of sitagliptin: a subanalysis of the JAMP study

H. Nunome, H. Sakura, N. Hashimoto, K. Sasamoto, H. Ohashi, S. Hasumi, N. Ujihara, T. Kasahara, O. Tomonaga, M. Honda, Y. Iwamoto, for the JAMP Study Investigators 158

Efficacy and safety of nateglinide plus sitagliptin combination therapy in type 2 diabetes patients inadequately controlled by sitagliptin monotherapy: a phase 3, multicenter, open-label, long-term study

T. Hirose, C. Saitoh, I. Oikawa, N. Kondo 168

Development of a novel estimation method for hemoglobin A1c using glycated albumin in type 2 diabetes mellitus patients with end-stage renal disease

A. Nakamura, R. Kodera, N. Sakamoto, H. Ujike, J. Wada, K. Shikata, H. Makino 179

Low body mass index and old age are useful in predicting the hemoglobin A1c-lowering effect of switching from sitagliptin to dulaglutide in Japanese patients with type 2 diabetes mellitus: a single-center, open-label, single-arm, pilot study

T. Iwasaki, T. Kessoku, T. Higurashi, M. Taguri, M. Yoneda 189

CASE REPORT

A case of hyperinsulinemic hypoglycemia related with a calcimimetic agent

S. Takashima, T. Narita, H. Otomo, T. Shimizu, Y. Yamada 196

SHORT COMMUNICATION

Effect of switching from conventional continuous subcutaneous insulin infusion to sensor augmented pump therapy on glycemic profile in Japanese patients with type 1 diabetes

A. Matsuoka, Y. Hirota, S. Urai, T. Hamaguchi, T. Takeuchi, H. Miura, N. Suematsu, A. So, T. Nakamura, H. Komada, Y. Okada, K. Sakaguchi, W. Ogawa 201

Update: October 3, 2018